South African Core Lab Adopts Affymetrix Technology for Genomic Studies
News Oct 08, 2008
Affymetrix Inc. has announced that one of South Africa’s largest public core labs has begun offering genomic research on the Affymetrix GeneChip® platform. The Centre for Proteomic and Genomic Research (CPGR) is using many Affymetrix GeneChip arrays, such as the exon array and the SNP Array 6.0, to explore applications with molecular diagnostics potential, large-scale genotyping and novel ways of advancing drug research and development across the country.
The CPGR supports scientists particularly in biomedicine and plant biotechnology. It has a particular interest in translational research, advancing scientific findings from the bench into the clinic. The Centre was founded in 2006 to provide analytical services, technical expertise, project support and collaborative research capabilities in genomics and proteomics.
“At the CPGR, our aim is to facilitate high-quality research and enable the growth of existing southern African biotech companies,” said Reinhard Hiller, Ph.D., managing director of the CPGR. “The range of projects we work on is particularly diverse, so we appreciate the ability of Affymetrix to offer products that meet all our customers’ needs, from toxicology to gene expression and genotyping.”
“The CPGR has assembled a team of world-class scientists to nourish the development of new biotech leaders by translating academic research into novel intellectual property and commercial ventures,” said Kevin King, president of Affymetrix.
”With its adoption of the entire portfolio of array products available on our integrated microarray platform, the Centre is setting new standards for microarray-based research which we believe will lead to important solutions for some of the region’s most pressing diseases.”
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.